Skip to main content
. 2017 Dec 4;8(67):111631–111641. doi: 10.18632/oncotarget.22881

Figure 4. Changes in renal histopathology of mice with experimental MN as shown by immunofluorescence staining for C3.

Figure 4

The NC group (A–C) and MN group (D–F) were treated with PBS (A and D), etanercept (MN-Eta; B and E), or preligand assembly domain fusion protein (MN-PLAD; C and F). Quantitative data for immunofluorescence staining of C3 are shown in (G).